
	Where results make sense

Topic: Pierre Fabre Group

Related Topics

Shire Pharmaceuticals

Pharmaceutical company

Abbott Laboratories

List of pharmaceutical companies

Lists of companies

Alkaloid

Eli Lilly and Company

GlaxoSmithKline

Cipla

List of British companies

Novartis

Bayer

List of French companies

List of Slovenian companies

Merck

	Pierre Fabre: A very french company
		He said that there were plenty of successful companies wanting to work with Pierre Fabre to help it exploit its rich research and development pipeline and that, as long as this remained the case, the company would continue to stand aside from the current spate of merger and acquisition activity.
		The collaboration between Pierre Fabre and the CNRS is a long and important one.
		Pierre Fabre has circumvented this problem by the use of superacidic chemistry, which involves reacting vinca alkaloids with a mixture of a Lewis acid and hydrogen fluoride in a Teflon reaction vessel.
	www.pharmj.com /editorial/20000805/articles/pierrefabre.html (1732 words)

	Reference.com/Encyclopedia/Laboratoires Pierre Fabre
		Laboratoires Pierre Fabre is a multinational pharmaceutical and cosmetics company based in Castres, France, near Toulouse.
		Founded in 1961 by Pierre Fabre, it is present in over 130 countries and has more than 9,000 employees (in 2003), 34% of whom are internationally-based.
		Pierre Fabre is best known for its vinorelbine (Navelbine), an anticancer drug of the vinca alkaloid class.
	www.reference.com /browse/wiki/Pierre_Fabre_Group (192 words)

	BioPortfolio News : Novacea and Pierre Fabre Medicament Enter Into Partnership for the Development and ...
		As studies have shown that 89% of cancer patients express aclear preference for oral chemotherapy assuming equal efficacy and sideeffects (Journal of Clinical Oncology, January 1997), Pierre Fabre has workedtoward the goal of improving quality of life for cancer patients with aneffective and better tolerated anti cancer agent.
		With more than1,100 researchers, Pierre Fabre Medicament dedicates 23 percent of its annualsales to research and development in five major therapeutic areas in terms ofpublic health: oncology (the priority RandD area of Pierre Fabre Medicament with50% of all RandD expenses), central nervous system, cardiology, internalmedicine/urology and dermatology.
		Pierre Fabre currently markets, directly orthrough its licensees, oral and I.V. vinorelbine in over 80 countriesthroughout the world.
	www.bioportfolio.com /july_05/26_07_2005/Novacea_and_Pierre_Fabre.html (864 words)

	Pierre Fabre Medicament Signs License Agreement With Pharmagenesis for Anti-Cancer Drug Based on Chinese Herbs :: News ...
		Pierre Fabre Medicament is developing a second oncology product named Vinflunine for the treatment of ovarian, bladder, lung and breast cancer.
		The Pierre Fabre Group, a privately owned French company, is organized into four separates branches: ethical pharmacy (with an emphasis in oncology, central nervous system and cardiovascular), consumer pharmaceuticals, dermo-cosmetics and homeopathy.
		The Pierre Fabre Medicament Group, via its Pierre Fabre Oncologie business unit, is a major player in the field of oncology.
	www.npicenter.com /anm/templates/newsATemp.aspx?articleid=4106 (666 words)

	Healthcare Sales & Marketing Network News: Bristol-Myers Squibb and Pierre Fabre Medicament S.A. Enter Into Agreement ...
		Pierre Fabre Medicament will be responsible for the development and marketing of Javlor in all other countries, including Europe.
		Leveraging years of research and novel chemistry, the scientists at the Pierre Fabre Research Center were able to produce a new generation product that exhibits unique pharmacologic properties that both companies believe may provide a safe and effective treatment for people with cancer.
		Pierre Fabre Medicament, the pharmaceutical branch of the Pierre Fabre Group, made Research and Development its core business and the key to its future.
	salesandmarketingnetwork.com /news_release.php?ID=15292 (897 words)

	ExonHit: News & Events - ExonHit Therapeutics and Biomerieux-Pierre Fabre form strategic alliance in cancer ...
		Based on bioMérieux-Pierre Fabre' s clinical expertise (biopsies and blood samples from patients with breast or colon cancers), ExonHit Therapeutics will leverage its core DATAS (Differential Analysis of Transcripts with Alternative Splicing) technology to define genetic signatures that will then be compiled on its analytical macro-arrays Proof-Hit™.
		The BioMérieux - Pierre Fabre Group is organized into five branches of activity: BioMérieux, Pierre Fabre Medicaments, Pierre Fabre Dermo-Cosmetics, Transgène and Dolisos.
		Its stated ambition is to build up a health group that is innovative, international and responds to the issues of the medicine of tomorrow.
	www.exonhit.com /html/news/2001_12_06.htm (726 words)

	Cypress Bioscience Revises Milnacipran License With Pierre Fabre Medicament to Improve Economic Terms and Expand the ...
		Pierre Fabre Medicament will continue to have the right to manufacture the active ingredients used in any products commercialized under the agreement.
		Pierre Fabre Medicament also has certain rights to negotiate a license for rights outside North America to new formulations and new salts developed by Cypress.
		The Pierre Fabre Group, a privately owned French company, is organized into four separate branches: ethical pharmacy (with an emphasis in oncology, central nervous system and cardiovascular), consumer pharmaceuticals, dermo- cosmetics and homeopathy.
	www.freshnews.com /cgi-bin/jsj_news/print.cgi?article_ID=15021 (950 words)

	Read more about Pierre Fabre - Dermo-Cosmetique - Oktal Pharma d.o.o.
		Pierre Fabre, a pharmacist from Castres in south-western France, founded Laboratories Pierre Fabre Medicament.
		PIERRE FABRE dermatological cosmetic products have become renowned and accepted because of the technological research based on strict pharmaceutical regulations and studies into plant properties, which is the unique feature of this manufacturer.
		The group PIERRE FABRE with his pharmaceutical orientation has become a model in the field of dermatological cosmetics, and a reliable partner of pharmacists in France, Spain, Italy, Portugal, Greece, Mexico, etc.
	www.oktal-pharma.hr /en/zastupstva/12 (186 words)

	Laboratories Pierre Fabre - Presentation & figures (Site not responding. Last check: 2007-11-01)
		Pierre Fabre RandD 's mission is to discover and develop original compounds obtained by chemical synthesis or from biological sources.
		More than 1400 people split between 12 specialised sites in France and Spain are active in developing innovative therapeutic solutions in response to major problems in public health in the area of drugs and in the area of dermo-cosmetic preparations.
		The Phytofilière® is part of Pierre Fabre Laboratories.
	www.pierre-fabre.com /common/0,4157,2072_2756_0_en_US_0,00.html (241 words)

	Laboratories Pierre Fabre - Pharmacy (Site not responding. Last check: 2007-11-01)
		Pierre Fabre Médicament is the 2nd largest independent French pharmaceutical laboratory, and orients its development on specifically targeted therapeutic lines.
		One of the Group's fundamental values is the priority it gives to the allocation of resources.
		A reputation of top-level scientific, clinical and therapeutic know-how, which has made the Pierre Fabre group one of Europe's leaders in the cancer field.
	www.pierre-fabre.com /common/0,4157,2072_11978040_0_en_US_0,00.html (197 words)

	MILLENIA HOPE - A Biopharma Company
		The Pierre Fabre Group is a world leader in the discovery, development and commercialization of plant-derived pharmaceutical and dermo-cosmetic products.
		The Pierre Fabre Group and Millenia Hope Biopharma are pleased to have created this association and look forward to future collaborations.
		Employing more than 1,400 researchers, the Pierre Fabre Group spends 25% of its annual revenues on RandD mainly in five therapeutic fields: oncology (Pierre Fabre Medicaments priority with 50% of total RandD spending), central nervous system, cardiology, internal medicine/urology and dermatology.
	www.milleniahope.com /more_news_articles/2006_06_22_0830ET.htm (387 words)

	Press release: MAT
		Such a collaboration clearly illustrates the Pierre Fabre strategic decision to move aggressively into the field of targeted biotherapy in Oncology" said Dr Jacques Kusmierek, Research and Development Director and President of the Pierre Fabre Research Institute (IRPF).
		The Institut de Recherche Pierre Fabre, belongs to the Pierre Fabre Group, the second largest independent laboratory in France, employing some 9 000 people, and having achieved 1.47 billion euros in sales in 2004.
		With more than 1 000 researchers, Pierre Fabre Médicament dedicates 25 % of its annual sales to RandD, in five major therapeutic areas in terms of public health: oncology (the top priority, with 50 % of all RandD budget), central nervous system, cardiology, internal medicine/urology, dermatology.
	www.genopole.org /html/en/presse/communiques/060209-comm-mat-en.htm (444 words)

	Executive Briefing: Pierre Fabre: Time to Reap R&D Rewards In-House (Site not responding. Last check: 2007-11-01)
		These and likely more to follow validate the quality and scope of the group’s research, but they will also, the company hopes, provide it with the financial wherewithal to achieve its ambitions in pharmaceuticals.
		Pierre Fabre is in no hurry to transform itself overnight, however.
		Pierre Fabre may not—yet—have shown the commercial drive of some of its peers, but its wide-ranging research operations and growing band of high-profile partners challenge those who dismiss Europe’s mid-sized, family-owned groups as uncompetitive.
	www.windhover.com /contents/monthly/exex/e_2005800116.htm (284 words)

	AstraZeneca and Pierre Fabre collaborate on clinical trial programme for IRESSA™ (ZD1839) in combination with ...
		Commenting on the collaboration, Pierre Fabre representatives said, "We are delighted to be working with AstraZeneca and we hope the combination of NAVELBINE® ORAL and 'Iressa' will provide patients with new treatment options in a number of different tumour types in the future."
		Pierre Fabre Médicament support a strong and active Research and Development policy : 20 % of turnover is dedicated to new drug discovery in oncology, CNS and cardiovascular diseases, and immunology.
		Pierre Fabre Oncologie is a specialized department of Pierre Fabre Médicament organised as a business unit specifically dedicated to the development (preclinical - clinical) and commercial activities of the Pierre Fabre Group in Onco-haematology.
	www.astrazeneca.com /pressrelease/434.aspx (953 words)

	Pharmacy Choice - Pharmaceutical News - Novacea and Pierre Fabre Medicament Enter Into Partnership for the Development ...
		Pierre Fabre will manufacture the product for clinical trials and any subsequent commercial sales.
		With more than 1,100 researchers, Pierre Fabre Medicament dedicates 23 percent of its annual sales to research and development in five major therapeutic areas in terms of public health: oncology (the priority RandD area of Pierre Fabre Medicament with 50% of all RandD expenses), central nervous system, cardiology, internal medicine/urology and dermatology.
		Pierre Fabre currently markets, directly or through its licensees, oral and I.V. vinorelbine in over 80 countries throughout the world.
	www.pharmacychoice.com /news/article.cfm?Article_ID=9523 (1049 words)

	Pharmalicensing.com: Pierre Fabre SA
		The Pierre Fabre Group, the second-largest independent laboratory in France, employs about 9,300 people and achieved sales of 1.47 billion euros in 2004.
		Pierre Fabre has a global experience in developing and marketing ethical medicine, health care (including OTC, dental and phyto nutritherapy products) and dermo-cosmetics products, in regulatory affairs and in manufacturing.
		With more than 1,100 researchers, Pierre Fabre Medicament dedicates 23 percent of its annual sales to research and development in five major therapeutic areas in terms of public health: oncology (the priority R&D area of Pierre Fabre Medicament with 50% of all R&D expenses), central nervous system, cardiology, internal medicine/urology and dermatology.
	pharmalicensing.com /company/showall/10257 (253 words)

	Center of Immunology Pierre Fabre - Welcome to the Center of Immunology Pierre Fabre (Site not responding. Last check: 2007-11-01)
		A center of excellence for biotechnology, the Center of Immunology Pierre Fabre (CIPF) is developing research programs in the field of cancer immunotherapy, in particular the identification of therapeutic monoclonal antibodies.
		Research undertaken at the CIPF up today has lead to the development of the first clinical antibody of the Pierre Fabre Group.
		Located in France, close to the biotech heart of Geneva, the CIPF is a part of Pierre FABRE Laboratories (over 9000 people in France and overseas).
	www.cipf.com /public/cipf/html/en/home/home.php (251 words)

	Laboratoires Pierre Fabre
		The parent company, Pierre Fabre, (est.1961) has seen its operations grow in two main businesses: Pharmacy and Cosmetics.
		In its decision-making, the senior management of the Pierre Fabre SA group is perceptive to the need to increase the international scope of its operations.
		The application Decision of Infor was the first application that the group deployed internationally, and took account of all aspects of the structure of Laboratoires Pierre Fabre; it made a significant improvement to the time taken for analysis, drafting and follow-up of the budget.
	www.aexis.com /LPF.htm (304 words)

	Eau Thermale Avene - About Avene Dermatological Laboratories
		Pierre Fabre Dermo-Cosmetique was the first skin cosmetics laboratory in Europe within the pharmaceutical branch.
		Dermatology is one of Pierre Fabre Dermo-Cosmetique's two main areas of specialization and expertise.
		Avene Dermatological Laboratories and Eau Thermale Avene operate under the umbrella of Pierre Fabre Dermo-Cosmétique, a division of Pierre Fabre Group, the second largest independent pharmaceutical company in France.
	www.aveneusa.com /physicians/aboutlabs/default.asp (341 words)

	CNW Telbec
		CASTRES, France, and WILMINGTON, Del., June 22 /CNW/ -- Les Laboratoires Pierre Fabre, a privately held company, and Millenia Hope Inc., a Biopharma Corporation (OTC Bulletin Board: MLHP), are pleased to announce that Pierre Fabre Medicament and Millenia Hope Biopharma (MHB), the Canadian subsidiary of Millenia Hope Inc., have finalized an important partnership.
		ABOUT LES LABORATOIRES PIERRE FABRE: The Pierre Fabre Group (PFG), the second largest independent R&D laboratory in France, employs 8,700 people and had revenues of 1,48 billion euro in 2005, of which 44% was achieved internationally.
		Employing more than 1,400 researchers, the Pierre Fabre Group spends 25% of its annual revenues on R&D mainly in five therapeutic fields: oncology (Pierre Fabre Medicaments priority with 50% of total R&D spending), central nervous system, cardiology, internal medicine/urology and dermatology.
	www.cnw.ca /en/releases/archive/June2006/22/c5429.html (485 words)

	Cengent Therapeutics Signs Crystal Structure Determination Contract with Pierre Fabre.
		In this collaboration, Cengent will provide Pierre Fabre Research Institute with X-ray crystallography services, enabling researchers to view high-resolution structures of a human target in Oncology.
		Information obtained from X-ray crystallography structure of the target assist Pierre Fabre Research Institute in further structure-based lead design and optimization, enhancing the company’s ability to develop drug candidates.
		The Pierre Fabre Group (http://www.pierre-fabre.com) the second-largest independent laboratory in France, employs some 9,000 people, and achieved 1.43 billion euros in sales in 2003.
	www.addpr.com /articles/biotechnology/902.html (579 words)

	Fabre - Wikipedia, the free encyclopedia
		Fabre is a surname, and may refer to:
		Henri Fabre, French aviator and inventor of Le Canard
		Pierre Fabre Group, a pharmaceutical and cosmetics company
	en.wikipedia.org /wiki/Fabre (101 words)

	Laboratoires Pierre Fabre; Millenia Hope Inc. :: Laboratoires Pierre Fabre and Millenia Hope Biopharma Enter Into an ... (Site not responding. Last check: 2007-11-01)
		Laboratoires Pierre Fabre and Millenia Hope Biopharma Enter Into an Important Collaborative Partnership
		CASTRES, France, and WILMINGTON, Del., June 22 /PRNewswire/ -- Les Laboratoires Pierre Fabre, a privately held company, and Millenia Hope Inc., a Biopharma Corporation (OTC: MLHP) (BULLETIN BOARD: MLHP), are pleased to announce that Pierre Fabre Medicament and Millenia Hope Biopharma (MHB), the Canadian subsidiary of Millenia Hope Inc., have finalized an important partnership.
		The Pierre Fabre Group (PFG), the second largest independent RandD laboratory in France, employs 8,700 people and had revenues of 1,48 billion euro in 2005, of which 44% was achieved internationally.
	sev.prnewswire.com /biotechnology/20060622/NYTH01022062006-1.html (434 words)

	René Furterer Inc. Selects PFSweb for Business Process Infrastructure, Fulfillment, Transportation and Logistics ...
		René Furterer, a wholly owned subsidiary of Pierre Fabre Dermocosmetique France, which in turn is part of the Pierre Fabre Group based in Paris, is dedicated to the care, improvement and beautification of hair.
		This global brand is Pierre Fabre’s entry into the U.S. markets along with such other brands as Klorane and Avene.
		Company founder René Furterer has dedicated 30 years of his life to hair care, joining forces with Pierre Fabre Laboratories in 1979 and benefiting from leading research and scientific development at the pharmaceutical company.
	www.emediawire.com /releases/2004/9/emw154579.htm (1168 words)

	Bristol-Myers Squibb - Alliances - News - News updates.
		Pierre Fabre Médicament S.A. and Bristol-Myers Squibb enter into agreement to develop and commercialize oncology treatment
		The two companies have entered into an agreement to develop and commercialize an investigational compound currently in Phase III clinical trials for the potential treatment of bladder and non-small cell lung cancer, and Phase II clinical trials for the potential treatment of breast and ovarian cancer.
		The collaboration underlines the expertise of our group's research department in the area of oncology, our main research area," said Dr. Jean-Pierre Couzinier, Pierre Fabre Médicament Chief Operating Officer.
	www.bms.com /alliances/news/updates/data/fg_alliances_news_4499.html (1829 words)

	Amazon.com: "Pierre Fabre": Key Phrase page (Site not responding. Last check: 2007-11-01)
		See all pages with references to Pierre Fabre.
		from the GlaxoWellcome and SmithKline Beecham groups, the group at Pierre Fabre also investigated analogues of the 3-arylpropylamines 1161.
		Pierre Fabre); the high sebum-absorbing power of the cyclodextrin is highlighted.
	www.amazon.com /phrase/Pierre-Fabre (345 words)

Try your search on: Qwika (all wikis)